Clinical Progress of Aerie Pharmaceuticals’ Rhopressa and Roclatan

Aerie: Bringing Rhopressa and Roclatan into US glaucoma markeПодробнее

Aerie Pharmaceuticals - OIS@ASCRS 2015Подробнее

Aerie Pharmaceuticals, Inc.Подробнее

Aerie COO Mitro Provides Staffing, Pipeline UpdateПодробнее

Aerie PharmaceuticalsПодробнее

Aerie Looks for Rhopressa NDA in Q3Подробнее

Aerie Pharmaceuticals - OIS@ASCRS (2018)Подробнее

Aerie Pharmaceuticals Using ROCK Inhibitors to Change Glaucoma Management (OIS@AAO 2016)Подробнее

Aerie Pharmaceuticals Reports Strong Progress in Retinal ProgramПодробнее

Aerie Pharmaceuticals: Moving Beyond Glaucoma (OIS@ASRS 2016)Подробнее

Vince Anido, PhD of Aerie Pharmaceuticals Discusses New Product Lines at OIS@ASRS 2019Подробнее

How Does Rhopressa WorkПодробнее

Mitro Quizzed on Aerie’s Three RsПодробнее

Aerie Pharmaceuticals: Building the Next Major Ophthalmologic CompanyПодробнее

Aerie Plans Next Step after RhopressaПодробнее

Aerie Pharmaceuticals - Public Company Showcase at Ophthalmology Innovation Summit @ ASRS 2019Подробнее

Aerie Pharmaceuticals - OIS@AAO 2015Подробнее

Aerie Pharmaceuticals - Innovation Showcase at Ophthalmology Innovation Summit @ ASCRS 2019Подробнее